21 August 2018 - Bristol-Myers Squibb is pricing blockbuster cancer drug Opdivo in China at little more than half the cost it goes for in the U.S., it was reported Tuesday.

Chinese regulators approved Opdivo to treat patients with non-small-cell lung cancer in June. A report from the news site Stat says Opdivo will cost $84,000 per year in China, as opposed to roughly $150,000 in the U.S.

The pharmaceutical company told Investor's Business Daily that it's still working with the government in China to iron out pricing. Bristol wouldn't comment on the price put out in Stat's news report.

Read Investors Business Daily article